Dopo l'orario di chiusura: 1.53

Inflarx N V (IFRX)

Inflarx N V Borsa (IFRX) Ultime notizie

Inflarx N V (IFRX)

Inflarx N V Borsa (IFRX) Ultime notizie

InflaRx shares maintain Buy rating from H.C. Wainwright on Gohibic trial analysis - Investing.com

InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright - Defense World

InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright - MarketBeat

InflaRx (NASDAQ:IFRX) Given "Buy" Rating at HC Wainwright - MarketBeat

InflaRx reports promising HS treatment results at EADV Congress - Investing.com

InflaRx presents e-poster presentation of post hoc analysis of SHINE study - TipRanks

InflaRx Presents Post Hoc Analysis of SHINE Trial of - GlobeNewswire

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress - StockTitan

InflaRx Announces Participation in September Investor Events - Yahoo Finance UK

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - Yahoo Finance UK

InflaRx (NASDAQ:IFRX) Stock Price Up 1.3% - MarketBeat

InflaRx (NASDAQ:IFRX) Shares Up 1.3% - Defense World

InflaRx reports promising data on oral C5aR inhibitor INF904 - Investing.com

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human - EIN News

InflaRx reports promising data on oral C5aR inhibitor INF904 By Investing.com - Investing.com UK

InflaRx presents new preclinical findings for INF904 - TipRanks

InflaRx Presents New Preclinical Findings for INF904 at the - GlobeNewswire

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - StockTitan

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - Yahoo Finance

InflaRx (NASDAQ:IFRX) Short Interest Down 9.2% in August - MarketBeat

InflaRx Announces Participation in September Investor Events - GlobeNewswire

InflaRx Announces Participation in September Investor Events - StockTitan

Short Interest in InflaRx (NASDAQ:IFRX) Rises By 281.4% - MarketBeat

InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

InflaRx N.V. Reports Mid-Year Financial Results - TipRanks

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan

InflaRx reports Q2 EPS (24c), consensus (22c) - TipRanks

InflaRx (IFRX) Set to Announce Earnings on Thursday - Defense World

InflaRx (IFRX) to Release Earnings on Thursday - MarketBeat

InflaRx to Report Second Quarter 2024 Results on August 8, 2024 - GlobeNewswire

InflaRx to Report Second Quarter 2024 Results on August 8, 2024 - StockTitan

InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases - GlobeNewswire

InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases - StockTitan

Vasculitis Treatment Market with Tremendous growth by 2031 – Glaxosmithkline plc, Amneal Pharmaceuticals, Inc., ChemoCentryx, InflaRx N.V – TIMC - TIMC

InflaRx (NASDAQ:IFRX) Short Interest Up 151.1% in June - American Banking and Market News

Short Interest in InflaRx (NASDAQ:IFRX) Expands By 151.1% - MarketBeat

Short Interest in InflaRx (NASDAQ:IFRX) Rises By 151.1% - Defense World

InflaRx Announces $75M Share Sales Agreement - TipRanks

InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Lifestyle Australia

InflaRx (NASDAQ:IFRX) Short Interest Update - MarketBeat

What Kind Of Investors Own Most Of InflaRx N.V. (NASDAQ:IFRX)? - Yahoo New Zealand News

SEC Form 424B5 filed by InflaRx N.V. - Quantisnow

InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo New Zealand News

InflaRx (NASDAQ:IFRX) Receives “Buy” Rating from HC Wainwright - Defense World

InflaRx's ARDS drug selected for BARDA Phase 2 study - Investing.com India

Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com

Iron Mountain executive sells over $547k in company stock By Investing.com - Investing.com UK

InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed ... - WICZ

InflaRx's GOHIBIC (Vilobelimab) Selected for First - GlobeNewswire

InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed ... - StockTitan

InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS) - Yahoo Finance

InflaRx's (IFRX) Buy Rating Reaffirmed at HC Wainwright - Defense World

InflaRx's (IFRX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

InflaRx Hosts R&D Event Highlighting the Promise of INF904 - GlobeNewswire

InflaRx Hosts R&D Event Highlighting the Promise of INF904 - Yahoo Finance

InflaRx (NASDAQ:IFRX) Trading Up 10.5% - MarketBeat

InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment - Yahoo Movies UK

Was InflaRx N.V. (IFRX)'s session last reading good? – US Post News - US Post News

InflaRx shares additional data, new analysis of PANAMO Phase III trialTipRanks.com - TipRanks

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy ... - GlobeNewswire

InflaRx reports reduced mortality in COVID-19 study By Investing.com - Investing.com

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy ... - Yahoo Finance

Are Options Traders Betting on a Big Move in InflaRx (IFRX) Stock? - Yahoo Movies UK

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators - Yahoo Finance

InflaRx to Post FY2024 Earnings of ($0.85) Per Share, Leerink Partnrs Forecasts (NASDAQ:IFRX) - MarketBeat

FY2024 EPS Estimates for InflaRx Raised by Leerink Partnrs (NASDAQ:IFRX) - Defense World

Simile a IFRX